진행성 핵상마비 임상시험 : 개발 동향 및 분석(2026년)

Progressive Supranuclear Palsy (PSP) is a rare and rapidly progressive neurodegenerative disorder characterized by impaired balance, postural instability, movement abnormalities, cognitive dysfunction, speech difficulties, and ocular motor impairment. The disease belongs to a group of neurodegenerative conditions known as tauopathies, where abnormal accumulation of tau protein contributes to neuronal degeneration. PSP is associated with significant disability and reduced life expectancy, while currently available treatment options remain limited to symptomatic management. The absence of approved disease-modifying therapies has intensified global research efforts aimed at identifying effective therapeutic interventions.

Clinical trials analysis has become an essential component of the PSP research ecosystem, providing stakeholders with insights into trial design, pipeline progress, patient recruitment trends, therapeutic targets, competitive developments, and regulatory pathways. Pharmaceutical companies, biotechnology firms, research institutions, investors, and healthcare organizations increasingly rely on clinical trial intelligence to guide development strategies and evaluate emerging opportunities within the PSP therapeutic landscape.

Market Drivers

Increasing Focus on Rare Neurodegenerative Diseases

One of the primary drivers of market growth is the growing attention being given to rare neurodegenerative disorders with significant unmet medical needs. PSP remains an area of intense scientific interest due to its severe clinical burden and lack of effective disease-modifying treatments.

Government agencies, research organizations, and pharmaceutical companies are allocating greater resources toward understanding disease mechanisms and developing innovative therapies, contributing to increased clinical trial activity.

Expansion of Therapeutic Development Pipelines

The PSP therapeutic pipeline has expanded significantly in recent years as researchers investigate novel approaches targeting tau pathology, neuroinflammation, protein aggregation, and neurodegeneration.

The growing number of investigational therapies entering preclinical and clinical development stages is increasing demand for comprehensive clinical trials analysis and competitive intelligence.

Advancements in Biomarker Research

Biomarker development is improving the ability to diagnose PSP earlier, monitor disease progression, and evaluate treatment responses during clinical trials. Advances in neuroimaging, cerebrospinal fluid biomarkers, blood-based biomarkers, and digital assessment tools are enhancing trial design and patient selection.

Improved biomarker capabilities are expected to increase clinical trial efficiency and support the development of more targeted therapeutic approaches.

Favorable Orphan Drug Incentives

As a rare disease, PSP qualifies for orphan drug incentives in several major pharmaceutical markets. Regulatory benefits such as market exclusivity, fee reductions, tax credits, and accelerated review pathways are encouraging greater investment in PSP clinical development programs.

These incentives are helping attract new entrants and strengthen the overall clinical research landscape.

Market Restraints

Limited Patient Population

PSP is a rare disorder with a relatively small global patient population. Recruiting sufficient numbers of eligible patients for clinical studies can be challenging and may extend trial timelines.

Limited patient availability can also increase development costs and create operational complexities for sponsors.

Diagnostic Challenges

PSP is often misdiagnosed during its early stages due to symptom overlap with Parkinson's disease and other movement disorders. Delayed diagnosis can restrict access to appropriate clinical trial populations and complicate patient enrollment efforts.

The lack of universally adopted diagnostic biomarkers remains a challenge for clinical research.

High Clinical Development Risk

Neurodegenerative disease research involves substantial scientific uncertainty and elevated failure rates. Complex disease biology, variable disease progression, and the absence of validated surrogate endpoints can contribute to development challenges.

These factors may increase investment risk and affect the pace of therapeutic advancement.

Technology and Segment Insights

The global progressive supranuclear palsy clinical trials analysis market can be segmented by trial phase, therapy type, mechanism of action, sponsor type, study design, end user, and geography.

By trial phase, the market includes preclinical studies, Phase I trials, Phase II trials, Phase III trials, and post-marketing research activities. Phase II studies account for a significant share of ongoing clinical activity as many investigational therapies undergo efficacy and safety evaluation.

By therapy type, the market includes monoclonal antibodies, small molecules, biologics, gene therapies, RNA-based therapies, neuroprotective agents, and other emerging therapeutic platforms. Monoclonal antibodies and targeted biologics are receiving substantial attention due to their potential to address disease-specific pathological processes.

By mechanism of action, the market includes tau-targeting therapies, anti-inflammatory agents, neuroprotective treatments, protein aggregation inhibitors, synaptic function modulators, and regenerative medicine approaches. Tau-targeted therapies represent one of the most active areas of clinical investigation due to the central role of tau pathology in PSP progression.

By sponsor type, the market includes pharmaceutical companies, biotechnology firms, academic institutions, government research organizations, and collaborative research networks. Biotechnology companies account for a substantial portion of innovation within the PSP clinical development landscape.

By study design, the market includes randomized controlled trials, open-label studies, adaptive clinical trials, observational studies, and biomarker-driven clinical investigations. Adaptive trial designs are gaining popularity due to their ability to improve efficiency and optimize resource utilization.

By end user, the market serves pharmaceutical companies, biotechnology firms, contract research organizations, healthcare institutions, academic researchers, investors, and consulting organizations. Pharmaceutical and biotechnology companies remain the primary consumers of clinical trial intelligence and competitive analysis.

Technological advancements are transforming clinical trials through artificial intelligence, machine learning, advanced neuroimaging, wearable monitoring devices, digital biomarkers, electronic patient-reported outcomes, and real-world evidence platforms. These innovations support improved patient identification, enhanced trial monitoring, more accurate endpoint evaluation, and accelerated decision-making.

Geographically, North America dominates the market due to strong neurological research infrastructure, substantial clinical trial activity, supportive regulatory frameworks, and significant healthcare investment. Europe represents a major market supported by collaborative neuroscience research initiatives and established rare disease programs. Asia-Pacific is expected to experience notable growth due to expanding clinical research capabilities, increasing healthcare investments, and growing participation in global clinical development programs. Latin America and the Middle East & Africa are gradually improving clinical research infrastructure and patient access to specialized neurological care.

Competitive and Strategic Outlook

The competitive landscape is evolving rapidly as pharmaceutical companies, biotechnology firms, and academic institutions pursue innovative treatment approaches for PSP. Organizations are increasingly focused on developing therapies that target disease mechanisms, particularly tau pathology, while also exploring broader neuroprotective and anti-inflammatory strategies.

Strategic partnerships, licensing agreements, collaborative research programs, and co-development initiatives are becoming increasingly common as stakeholders seek to share expertise, reduce development risk, and accelerate clinical progress. These collaborations are helping organizations expand research capabilities and improve access to specialized patient populations and scientific resources.

Clinical trial intelligence is becoming a critical component of competitive strategy. Companies are closely monitoring pipeline developments, trial outcomes, biomarker advancements, and regulatory milestones to inform investment decisions and optimize development programs.

As more therapies progress through clinical evaluation, competition is expected to intensify, particularly among organizations developing disease-modifying treatments with the potential to address the underlying causes of PSP.

Conclusion

The global progressive supranuclear palsy clinical trials analysis market is poised for strong growth through 2031, supported by expanding research activity, growing orphan drug development initiatives, advancements in biomarker science, and increasing investment in rare neurodegenerative disease therapeutics. Clinical trials analysis remains essential for understanding pipeline dynamics, evaluating therapeutic opportunities, and supporting strategic decision-making across the healthcare industry. Although challenges related to patient recruitment, diagnostic complexity, and clinical development risk persist, continued scientific progress and expanding collaborative research efforts are expected to accelerate therapeutic innovation and improve future treatment prospects for patients living with progressive supranuclear palsy.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Progressive Supranuclear Palsy (PSP) Clinical Trials Landscape Overview
  • 1.1.1 Current Clinical Development Snapshot
  • 1.1.2 Key Pipeline Trends and Strategic Findings
  • 1.1.3 Innovation Themes Shaping PSP Drug Development
  • 1.1.4 Clinical Trial Activity Assessment
  • 1.1.5 Near-Term Catalysts and Value Inflection Points
• 1.2 Key Conclusions
  • 1.2.1 Most Advanced Clinical Programs
  • 1.2.2 Emerging Mechanistic Approaches
  • 1.2.3 Risk-Adjusted Development Outlook
  • 1.2.4 Commercialization Outlook

2. Pipeline Overview

• 2.1 Progressive Supranuclear Palsy Drug Development Landscape
  • 2.1.1 Historical Evolution of PSP Therapeutic Development
  • 2.1.2 Current Pipeline Maturity Assessment
  • 2.1.3 Pipeline Growth Trends
  • 2.1.4 Clinical Development Distribution by Phase
• 2.2 Pipeline Asset Inventory
  • 2.2.1 Total Active Assets
  • 2.2.2 Active versus Discontinued Programs
  • 2.2.3 Sponsor Diversity Assessment
  • 2.2.4 Academic versus Industry-Sponsored Programs
• 2.3 Clinical Trial Landscape Overview
  • 2.3.1 Ongoing Studies
  • 2.3.2 Completed Studies
  • 2.3.3 Recruiting Studies
  • 2.3.4 Planned and Upcoming Studies
• 2.4 Pipeline Historical Progression Analysis
  • 2.4.1 Phase Advancement Trends
  • 2.4.2 Clinical Attrition History
  • 2.4.3 Program Termination Analysis
  • 2.4.4 Lessons from Historical Development Failures

3. Disease & Unmet Need Analysis

• 3.1 Disease Overview
  • 3.1.1 Disease Definition and Classification
  • 3.1.2 Epidemiology Overview
  • 3.1.3 Disease Burden Assessment
  • 3.1.4 Mortality and Morbidity Trends
• 3.2 Disease Biology and Pathogenesis
  • 3.2.1 Tau Pathology
  • 3.2.2 Neurodegeneration Pathways
  • 3.2.3 Neuroinflammation Mechanisms
  • 3.2.4 Genetic and Molecular Drivers
• 3.3 Current Treatment Landscape
  • 3.3.1 Standard of Care Review
  • 3.3.2 Symptomatic Treatment Approaches
  • 3.3.3 Treatment Limitations
  • 3.3.4 Unmet Clinical Needs
• 3.4 Future Treatment Paradigm
  • 3.4.1 Disease-Modifying Therapy Potential
  • 3.4.2 Biomarker-Driven Development
  • 3.4.3 Precision Medicine Opportunities

4. Mechanism & Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 Tau Aggregation Inhibitors
  • 4.1.2 Tau Immunotherapies
  • 4.1.3 Tau Clearance and Degradation Approaches
  • 4.1.4 Neuroprotective Mechanisms
  • 4.1.5 Neuroinflammation Modulation
  • 4.1.6 Retrotransposon-Targeting Approaches
  • 4.1.7 Emerging Disease-Modifying Strategies
• 4.2 Mechanism Clustering Analysis
  • 4.2.1 Established Mechanisms
  • 4.2.2 Novel Mechanisms
  • 4.2.3 First-in-Class Candidates
  • 4.2.4 Best-in-Class Development Opportunities
  • 4.2.5 White Space Opportunity Mapping
• 4.3 Modality Analysis
  • 4.3.1 Small Molecule Therapeutics
  • 4.3.2 Monoclonal Antibodies
  • 4.3.3 Protein-Based Therapeutics
  • 4.3.4 Cell Therapy Approaches
  • 4.3.5 Gene Therapy Approaches
  • 4.3.6 RNA-Based Therapeutics
  • 4.3.7 Combination Therapy Concepts
• 4.4 Innovation Index Assessment
  • 4.4.1 Mechanistic Novelty Scoring
  • 4.4.2 Scientific Differentiation Analysis
  • 4.4.3 Translational Readiness Evaluation

5. Clinical Development Intelligence

• 5.1 Clinical Trial Design Benchmarking
  • 5.1.1 Trial Design Evolution
  • 5.1.2 Randomization Strategies
  • 5.1.3 Control Arm Selection
  • 5.1.4 Adaptive Trial Designs
• 5.2 Endpoint Benchmarking
  • 5.2.1 PSP Rating Scale Utilization
  • 5.2.2 Functional Outcome Measures
  • 5.2.3 Biomarker Endpoints
  • 5.2.4 Imaging-Based Endpoints
  • 5.2.5 Digital Biomarker Integration
• 5.3 Patient Enrollment Intelligence
  • 5.3.1 Recruitment Timelines
  • 5.3.2 Enrollment Challenges
  • 5.3.3 Geographic Recruitment Patterns
  • 5.3.4 Patient Retention Analysis
• 5.4 Clinical Trial Performance Analysis
  • 5.4.1 Sample Size Benchmarking
  • 5.4.2 Study Duration Assessment
  • 5.4.3 Dropout Rate Analysis
  • 5.4.4 Protocol Amendment Trends
• 5.5 Success and Failure Assessment
  • 5.5.1 Historical Success Rates
  • 5.5.2 Key Failure Drivers
  • 5.5.3 Biomarker Validation Challenges
  • 5.5.4 Regulatory Risk Factors

6. Global Progressive Supranuclear Palsy Clinical Trials Landscape Report Segmentation Analysis

• 6.1 By Clinical Trial Phase
  • 6.1.1 Early-stage
  • 6.1.2 Mid-stage
  • 6.1.3 Late Stage
• 6.2 By Route of Administration
  • 6.2.1 Oral
  • 6.2.2 Intravenous
  • 6.2.3 Others
• 6.3 By Modality
  • 6.3.1 Small Molecules
  • 6.3.2 Biologics
  • 6.3.3 Others
• 6.4 By Sponsor Type
  • 6.4.1 Pharmaceutical Companies
  • 6.4.2 Biotechnology Companies
  • 6.4.3 Academic and Non-Profit Sponsors

7. Probability of Success & Risk Analysis

• 7.1 Development Risk Framework
  • 7.1.1 Scientific Risk
  • 7.1.2 Clinical Risk
  • 7.1.3 Regulatory Risk
  • 7.1.4 Commercial Risk
• 7.2 Phase Transition Probability Modeling
  • 7.2.1 Preclinical-to-Phase I Probability
  • 7.2.2 Phase I-to-Phase II Probability
  • 7.2.3 Phase II-to-Phase III Probability
  • 7.2.4 Phase III-to-Approval Probability
  • 7.2.5 Overall Likelihood of Approval
• 7.3 Attrition Analysis
  • 7.3.1 Historical Attrition Trends
  • 7.3.2 Mechanism-Specific Attrition
  • 7.3.3 Modality-Specific Attrition
  • 7.3.4 Sponsor-Type Attrition Comparison
• 7.4 Risk-Adjusted Pipeline Assessment
  • 7.4.1 Risk-Adjusted Asset Valuation
  • 7.4.2 Risk-Adjusted Market Opportunity
  • 7.4.3 Portfolio Quality Assessment
• 7.5 Scenario Modeling
  • 7.5.1 Base Case Scenario
  • 7.5.2 Optimistic Scenario
  • 7.5.3 Conservative Scenario
  • 7.5.4 Sensitivity Analysis

8. Launch Timeline & Commercial Potential

• 8.1 Regulatory and Approval Outlook
  • 8.1.1 Expected Regulatory Milestones
  • 8.1.2 Approval Timeline Forecasts
  • 8.1.3 Potential Expedited Pathways
  • 8.1.4 Regulatory Risk Assessment
• 8.2 Launch Sequencing Analysis
  • 8.2.1 First-Mover Opportunities
  • 8.2.2 Competitive Entry Timing
  • 8.2.3 Market Access Considerations
  • 8.2.4 Launch Prioritization Framework
• 8.3 Commercial Opportunity Assessment
  • 8.3.1 Addressable Patient Population
  • 8.3.2 Pricing and Reimbursement Considerations
  • 8.3.3 Peak Sales Forecasting
  • 8.3.4 Revenue Scenario Modeling
• 8.4 Competitive Commercial Dynamics
  • 8.4.1 Market Share Capture Potential
  • 8.4.2 Competitive Differentiation Drivers
  • 8.4.3 Lifecycle Management Strategies

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
  • 9.1.1 Competitive Intensity Assessment
  • 9.1.2 Market Leadership Evaluation
  • 9.1.3 Innovation Leadership Analysis
• 9.2 Company-Wise Pipeline Strength Analysis
  • 9.2.1 Clinical Stage Leadership
  • 9.2.2 Innovation Leadership
  • 9.2.3 Portfolio Breadth Assessment
  • 9.2.4 Development Capability Assessment
• 9.3 Asset Concentration Analysis
  • 9.3.1 Leading Mechanisms
  • 9.3.2 Sponsor Concentration
  • 9.3.3 Development Risk Concentration
• 9.4 Leader versus Challenger Matrix
  • 9.4.1 Established Leaders
  • 9.4.2 Emerging Challengers
  • 9.4.3 High-Potential Innovators
  • 9.4.4 Strategic Positioning Assessment
• 9.5 Competitive Benchmarking Framework
  • 9.5.1 Clinical Differentiation
  • 9.5.2 Regulatory Positioning
  • 9.5.3 Commercial Readiness
  • 9.5.4 Probability-Adjusted Ranking

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Key Development Centers
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Key Development Centers
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Key Development Centers
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Key Development Centers
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Key Development Centers

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
• 11.3 Germany
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Key Sponsors
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Key Sponsors
• 11.5 France
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Key Sponsors
• 11.6 Italy
  • 11.6.1 Clinical Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Key Sponsors
• 11.7 Spain
  • 11.7.1 Clinical Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Key Sponsors
• 11.8 China
  • 11.8.1 Clinical Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Key Sponsors
• 11.9 Japan
  • 11.9.1 Clinical Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Key Sponsors
• 11.10 India
  • 11.10.1 Clinical Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Key Sponsors
• 11.11 South Korea
  • 11.11.1 Clinical Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Key Sponsors
• 11.12 Australia
  • 11.12.1 Clinical Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Key Sponsors
• 11.13 Brazil
  • 11.13.1 Clinical Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Key Sponsors
• 11.14 Mexico
  • 11.14.1 Clinical Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Key Sponsors
• 11.15 Saudi Arabia
  • 11.15.1 Clinical Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Key Sponsors
• 11.16 South Africa
  • 11.16.1 Clinical Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Key Sponsors

12. Deals & Investment Landscape

• 12.1 Licensing and Collaboration Activity
  • 12.1.1 Asset Licensing Transactions
  • 12.1.2 Co-Development Agreements
  • 12.1.3 Co-Commercialization Partnerships
  • 12.1.4 Strategic Alliances
• 12.2 Mergers and Acquisitions
  • 12.2.1 Asset Acquisitions
  • 12.2.2 Platform Acquisitions
  • 12.2.3 Portfolio Expansion Transactions
• 12.3 Financing and Capital Flows
  • 12.3.1 Venture Capital Investments
  • 12.3.2 Private Equity Activity
  • 12.3.3 Public Market Financing
  • 12.3.4 Non-Dilutive Funding Sources
• 12.4 Investment Attractiveness Assessment
  • 12.4.1 Capital Deployment Trends
  • 12.4.2 Investor Sentiment Analysis
  • 12.4.3 Future Funding Outlook

13. Future Outlook & Strategic Insights

• 13.1 Strategic Outlook for PSP Therapeutics
  • 13.1.1 Future Innovation Directions
  • 13.1.2 Emerging Scientific Breakthroughs
  • 13.1.3 Development Priorities Through 2035
• 13.2 Company Strategic Assessment
  • 13.2.1 Novartis AG
    • 13.2.1.1 PSP Development Strategy
    • 13.2.1.2 Competitive Positioning
    • 13.2.1.3 Future Opportunities
  • 13.2.2 Alzprotect
    • 13.2.2.1 PSP Development Strategy
    • 13.2.2.2 Competitive Positioning
    • 13.2.2.3 Future Opportunities
  • 13.2.3 Transposon Therapeutics
    • 13.2.3.1 PSP Development Strategy
    • 13.2.3.2 Competitive Positioning
    • 13.2.3.3 Future Opportunities
  • 13.2.4 Ferrer
    • 13.2.4.1 PSP Development Strategy
    • 13.2.4.2 Competitive Positioning
    • 13.2.4.3 Future Opportunities
  • 13.2.5 UCB
    • 13.2.5.1 PSP Development Strategy
    • 13.2.5.2 Competitive Positioning
    • 13.2.5.3 Future Opportunities
  • 13.2.6 Asceneuron
    • 13.2.6.1 PSP Development Strategy
    • 13.2.6.2 Competitive Positioning
    • 13.2.6.3 Future Opportunities
  • 13.2.7 TauC3 Biologics
    • 13.2.7.1 PSP Development Strategy
    • 13.2.7.2 Competitive Positioning
    • 13.2.7.3 Future Opportunities
• 13.3 Strategic Recommendations
  • 13.3.1 Opportunities for Developers
  • 13.3.2 Opportunities for Investors
  • 13.3.3 Opportunities for Licensing Partners
  • 13.3.4 Clinical Development Optimization Strategies

14. Methodology & Data Framework

• 14.1 Research Methodology
  • 14.1.1 Primary Research Framework
  • 14.1.2 Secondary Research Framework
  • 14.1.3 Data Validation Process
• 14.2 Data Sources
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Information System (CTIS)
  • 14.2.3 Regulatory Agency Filings
  • 14.2.4 Company Pipeline Disclosures
  • 14.2.5 Scientific Literature Sources
• 14.3 Asset Inclusion Criteria
  • 14.3.1 Verification Requirements
  • 14.3.2 Clinical Status Validation
  • 14.3.3 Mechanism Classification Framework
• 14.4 Forecasting Framework
  • 14.4.1 Probability of Success Model
  • 14.4.2 Risk Adjustment Methodology
  • 14.4.3 Revenue Forecast Methodology
  • 14.4.4 Scenario Analysis Methodology
• 14.5 Quality Assurance Framework
  • 14.5.1 Data Audit Procedures
  • 14.5.2 Source Traceability Standards
  • 14.5.3 Update and Revision Protocols
  • 14.5.4 Zero-Hallucination Validation Checklist